1. Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2. (February 2017) Authors: Sonke, G.S.; Hart, L.L.; Campone, M.; Erdkamp, F.; Janni, W.; Verma, S.; Villanueva, C.; Jakobsen, E.; Alba, E.; Wist, E.; Favret, A.M.; Bachelot, T.; Hegg, R.; Wheatley-Price, P.; Souami, F.; Sutradhar, S.; Miller, M.; Germa, C.; Burris, H.A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. (December 2016) Authors: André, F.; Stemmer, S.M.; Hortobagyi, G.N.; Burris, H.A.; Paluch-Shimon, S.; Campone, M.; Villanueva, C.; Chan, A.; Wist, E.; Marschner, N.; Bachelot, T.; Blau, S.; Janni, W.; Verma, S.; Conte, P.; Dhuria, S.; Yang, S.; Stegert, M.; Germa, C.; Arteaga, C.L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗